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Abstract
Coronary heart disease (CHD) is among the most serious worldwide health problems. Recent genetic studies have 
robustly identified a number of polymorphic loci throughout the genome that are associated with disease risk but it is 
certain that more remain to be discovered. It is well established that inflammation plays a key role in the 
pathophysiology of CHD. Determining whether or not polymorphisms in genes involved in the inflammatory cascade 
affect the risk of CHD is of considerable interest with respect to understanding the direction of the causal arrow 
between increased expression of inflammatory genes and CHD. Establishing an association between the variation in 
inflammatory genes and CHD would provide conceptual support for the use of appropriately specific anti-
inflammatory agents in CHD prevention and, potentially, suggest new therapeutic targets. This month in BMC Medicine, 
Benjamin Brown and colleagues adopt a family-based case-control association study design to address this question. 
In a large number of CHD cases and healthy sibling controls genotyped for 51 mainly coding single nucleotide 
polymorphisms (SNPs), they find evidence for the association of a common haplotype at the Interleukin-1 (IL-1) cluster 
with CHD which appears to be stronger in younger cases without hypercholesterolaemia. They also find suggestive 
evidence for an association between this same haplotype and hypercholesterolaemia. If replicated in other cohorts, 
these results could be of substantial importance in advancing the understanding of the way in which inflammatory 
genes affect coronary heart disease risk.
See the associated research paper by Brown et al: http://www.biomedcentral.com/1741-7015/8/5
Commentary
This month in BMC Medicine, Benjamin Brown and col-
leagues present a large genetic study which specifically
addresses the effect of polymorphisms in genes involved in
the inflammatory process on the risk of coronary heart dis-
ease (CHD) [1]. In this commentary, I discuss recent results
in the coronary disease genetics literature pertinent to the
findings of Brown et al., examine the difficulties inherent in
assigning causal roles to the measurements of particular
plasma biomarkers of inflammation in CHD and discuss the
approach sometimes termed 'Mendelian randomization',
which has in recent years been increasingly used to address
this issue.
Numerous epidemiological studies and large meta-analy-
ses have convincingly shown evidence for the association
between higher plasma levels of a number of the inflamma-
tory proteins coded for by inflammatory genes (most exten-
sively, C-reactive protein [CRP] but also some members of
the interleukin family) and CHD risk. However, the associ-
ations are less strong than those observed for 'classical' risk
factors such as low-density lipoprotein-cholesterol, and the
magnitude of the associations observed has tended to be
quite sensitive to the degree of adjustment for potential con-
founding factors that has been made [2-4]. This raises the
possibility that the association between such inflammatory
proteins and CHD risk is largely, or possibly entirely, due to
confounding or 'reverse causality' [5]. Reverse causal bias
can arise in situations when subclinical manifestations of a
disease process which starts early in life (such as CHD) are
already sufficient to cause elevations in candidate biomark-
ers at the time that a prospective cohort is ascertained, such
that an association is observed between baseline levels of
the biomarker and subsequent clinical manifestations of the
disease process. With respect to CHD and biomarkers of
inflammation, higher levels of CRP have been shown even
among children who have higher levels of 'classical' risk
factors for CHD, such as obesity [6-8]. Of course, if the
addition of plasma levels of particular factors to existing
risk algorithms significantly improves their predictive util-
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association could not be proved to be causal. However, a
strong presumption of causality is necessary before a partic-
ular gene product could be pursued as a potential therapeu-
tic target. For a number of plausible candidate
inflammatory genes, this remains an open question. Estab-
lishing robust associations between single nucleotide poly-
morphisms (SNPs) in such genes which affect the plasma
levels of the gene product and CHD would constitute strong
evidence in favour of a causal involvement in disease, an
approach sometimes termed 'Mendelian randomization' [9].
Genomewide association studies (GWAS) of CHD, in
which the genotypes at hundreds of thousands of common
genetic variants (SNPs) throughout the human genome are
compared in thousands of CHD cases and a similar number
of controls have, in recent years, had a substantial degree of
success in identifying loci robustly associated with CHD
[10-14]. Thus far, around a dozen loci have been detected.
Many have associations with plasma lipoprotein levels but
some, including the effect that has consistently been identi-
fied as the strongest (on chromosome 9p21), are uncorre-
lated with any of the 'classical' risk factors for CHD. It is
perhaps noteworthy that no GWAS has convincingly impli-
cated any of the inflammatory genes that are the subject of
Brown et al.'s analyses. However, one limitation of the
GWAS approach is that the heavy penalty for multiple test-
ing that must be imposed for assessing genotypes at very
many loci to some extent limits the power of the approach
to detect weak effects. Meta-analysis of GWAS datasets has
been carried out in order to attempt to address this issue
[15-17]. In the meta-analyses conducted so far, which have
included up to 25,000 cases, no strong associations with the
inflammatory genes studied by Brown et al. have been dis-
covered. However, due to the play of chance, it would not
be expected that even such studies would detect all the
common variants affecting CHD risk. Moreover, GWAS
analyses have, thus far, been confined to examining typed
variants one-by-one rather than in ordered series of geno-
types along chromosomal segments (haplotypes) during the
initial screening stage involving all SNPs. Therefore,
effects on risk conferred, not by genotype at one SNP but
by the interaction of multiple loci on a haplotype, could
have been missed. There is precedent for important effects
of this type. For example, the epsilon-2/epsilon-3/epsilon-4
isoform polymorphism in the Apolipoprotein E gene is
defined by the genotype at two nonsynonymous SNPs at
codons 112 and 158 of the protein. The ApoE isoform poly-
morphism has been shown in large studies to be strongly
associated with CHD risk (with a per-allele risk ratio of
around 1.3) [18], and yet SNP-by-SNP analysis in the
GWAS studies conducted thus far has consistently failed to
identify ApoE as a strong risk gene. Thus, even in the
GWAS era, there remains a place for more focused exami-
nations of candidate genes in large cohorts, particularly if
haplotype-specific effects are investigated.
Brown et al. examined the relationship between 51 com-
mon genetic polymorphisms in 35 genes involved in
inflammation and the risk of CHD, in a large collection of
2699 siblings from 891 families of whom 1154 had CHD.
They utilized statistical tests which took account of the
'overmatched' nature of family as opposed to unrelated con-
trols and adjusted, where possible, for the effects of 'classi-
cal' CHD risk factors. In unadjusted analyses, they found
evidence for an association between CHD and a long-range
three-locus haplotype spanning 52 Kb of the IL-1 gene
cluster. The haplotype is common (frequency 0.41), so even
the relatively small effect on CHD risk that was found
(odds ratio [OR] per copy 1.21; 95% CI [confidence inter-
val] 1.04 - 1.40; P = 0.006) could translate into a fairly sub-
stantial effect at the population level. However, after full
adjustment for classical risk factors, the result was no lon-
ger significant. This prompted Brown et al. to test whether
the association between the IL-1 cluster haplotype and
CHD could be mediated through a classical risk factor.
Intriguingly, a borderline significant association was
observed between hypercholesterolemia and the IL-1 risk
haplotype (OR 1.15; 95% CI 1.03-1.29; P = 0.01). Brown et
al. acknowledge the potential for the association with
hypercholesterolaemia to be confounded due to the strong
correlation between MI and treatment with statin drugs,
which was one of the criteria they used to define hypercho-
lesterolaemia. Nevertheless, the suggestion that the IL-1
haplotype adversely affects plasma lipids is one that merits
further study, possibly in a quantitative fashion in cohorts
without the high level of statin exposure present in the
study of Brown et al. It is perhaps noteworthy that joint
analyses of GWAS data from up to 40,000 individuals have,
not, thus far, shown any effect of the IL-1 locus on plasma
lipids [19-22], although, in general, haplotype analyses, as
noted above, have not featured in the screening stage of
such investigations. Genetic polymorphisms identified so
far that affect plasma lipid concentrations (with the excep-
tion of the effect of polymorphism at the apo(a) locus on
plasma levels of lipoprotein(a), which is substantial),
account for only a small fraction of the calculated heritabil-
ity of the lipid traits investigated. Indeed, this same pattern
has been observed for other quantitative phentotypes, such
as height, and all complex diseases so far studied using
GWAS. The majority of the effort to find what has been
termed the 'missing heritability' of complex traits is pres-
ently focused on the investigation of genetic variation not
captured in GWAS studies, such as rare variants using ultra-
high throughput sequencing and complex copy number
variants. However, the existence of long-range haplotype-
specific effects that can be detected by combinations of
SNPs, such as that illustrated by Brown and colleagues, is a
potential explanation for a proportion of the missing herita-
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other cohorts will be of substantial interest in the future.
In conclusion, the findings of this hypothesis-generating
study, if replicated, could be of considerable importance,
not only in elucidating the relationship between cytokine
genes and CHD risk but also, more generally, in signposting
the way towards identifying some of the 'missing heritabil-
ity' that genetic epidemiologists are seeking in the post-
GWAS era.
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